RDY
Dr. Reddy's Laboratories Ltd.

597
Mkt Cap
$1.05T
Volume
358,804.00
52W High
$16.17
52W Low
$12.26
PE Ratio
16.41
RDY Fundamentals
Price
$13.53
Prev Close
$13.41
Open
$13.49
50D MA
$14.36
Beta
0.41
Avg. Volume
860,515.19
EPS (Annual)
$0.8029
P/B
2.77
Rev/Employee
$138,447.28
Loading...
Loading...
News
all
press releases
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...
Business Wire·8d ago
News Placeholder
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
Zacks·21d ago
News Placeholder
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
Zacks·24d ago
News Placeholder
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Zacks·1mo ago
News Placeholder
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Zacks·1mo ago
News Placeholder
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Zacks·1mo ago
News Placeholder
Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains?
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1mo ago
News Placeholder
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Zacks·1mo ago
News Placeholder
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Zacks·1mo ago

Latest RDY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.